Search

Each record is a registered study, a systematic-review registration or a publication. A registered or ongoing study is not a finding, and animal or cell research does not show an effect in people. The same study can appear under more than one subject, so the number of records is not a count of independent studies. You can also search an exact DOI, PubMed ID, NCT or CRD number. How to read these records.

90 study records (showing up to 30 per record type)

• Registered trial NCT05775237 Completed (results not assessed here)
  An Investigator-initiated Trial to Assess the Effectiveness of Three Different Gummies (Curcumin Gummies, Vitamin C Gummies, and Vitamin B Complex Gummies) in Healthy Children
  Condition or outcome area: Healthy Children
  2023-05-01 · Subject: Vitamin C; D-Ascorbic acid; D01CWN; Cell C; Ronotec 100; P 1110; Suncoat VC 40; D-threo-hex-2-enoic acid gamma-lactone; Citrovit; 2-o-(beta-d-glucopyranosyl)-ascorbic acid_qt · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05761327 Completed (results not assessed here)
  Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis
  Condition or outcome area: Ulcerative Colitis
  2022-06-03 · Subject: Trans-Resveratrol; Resveratrol; (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19 · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05982197 Completed (results not assessed here)
  Curcumin Gel On Radiation Induced Oral Mucositis
  Condition or outcome area: Radiation-Induced Mucositis|Head and Neck Cancer
  2023-01-03 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05761327 Completed (results not assessed here)
  Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis
  Condition or outcome area: Ulcerative Colitis
  2022-06-03 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05775237 Completed (results not assessed here)
  An Investigator-initiated Trial to Assess the Effectiveness of Three Different Gummies (Curcumin Gummies, Vitamin C Gummies, and Vitamin B Complex Gummies) in Healthy Children
  Condition or outcome area: Healthy Children
  2023-05-01 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT06044142 Phase 1 Completed (results not assessed here)
  Curcumin VS Photo-bio-modulation Therapy of Oral Mucositis in Pediatric Patients Undergoing Anti-Cancer Non-invasive Treatment
  Condition or outcome area: Oral Mucositis|Pediatric Cancer
  2023-03-15 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05688488 Phase 1 / Phase 2 Not completed: Recruiting
  Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords
  Condition or outcome area: Glottic Web of Larynx|Laryngeal Stenosis|Glottic Carcinoma|Laryngeal Leucoplakia|Laryngeal Polyp|Laryngeal Papilloma
  2023-05-05 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT06177483 Completed (results not assessed here)
  Bioavailability Evaluation of CurQ+ Curcumin Formulation
  Condition or outcome area: Bioavailability
  2024-03-01 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05714670 Phase 2 Not completed: Recruiting
  The Effect of Curcumin on the Clinical Outcome of Pediatric Patients With Active Lupus Nephritis
  Condition or outcome area: Lupus Nephritis|SLE Nephritis
  2023-04-01 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05753436 Phase 2 Not completed: Recruiting
  Curcumin's Effect on Diabetic Patients With Atherosclerotic Cardiovascular Risk
  Condition or outcome area: Diabetes Mellitus, Type 2|Dyslipidemias|Hypertension
  2023-07-01 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT06080841 Not completed: Recruiting
  Curcumin Supplementation in Cervical Cancer
  Condition or outcome area: Locally Advanced Cervical Cancer
  2023-04-19 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05774704 Phase 1 / Phase 2 Not completed: Recruiting
  Curcumin and Retinal Study
  Condition or outcome area: Bioavailability|Gut Microbiome|Safety
  2023-08-21 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05819632 Not completed: Recruiting
  Clinical Comparison of Application of Curcumin Gel in Pain Management After Free Gingival Graft Harvesting
  Condition or outcome area: Palate; Wound
  2022-11-01 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05761327 Completed (results not assessed here)
  Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis
  Condition or outcome area: Ulcerative Colitis
  2022-06-03 · Subject: Cis-Resveratrol; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]resorcinol; CHEBI:36002; Tocris-1418; NCGC00024003-02; NCGC00015894-01; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05770791 Phase 1 Not completed: Recruiting
  Comparative Effects of Using Black Seed and Cumin Seed on BCP of Obese Grade I
  Condition or outcome area: Obese
  2023-01-27 · Subject: Zi Ran Qin; 孜然芹; Cumin; Cuminum Cyminum · open the herb record · ClinicalTrials.gov
• Registered trial NCT06105840 Phase 1 / Phase 2 Not completed: Enrolling By Invitation
  Combination of Curcuminoid With Acupressure for Inflammation and Pain in the Elderly With Osteoarthritis Genu
  Condition or outcome area: Osteoarthritis, Knee
  2023-08-27 · Subject: Jiang Huang; 姜黄; Turmeric;Rhizome Of Common Turmeric; Rhizoma Curcumae Longae;Curcumae Longae Rhizoma · open the herb record · ClinicalTrials.gov
• Registered trial NCT06029023 Phase 1 Not completed: Recruiting
  Clinical And Radiographic Evaluation Of Nano-Propolis, Nano-Curcumin and MTA as Direct Pulp Capping Agents in Young Permanant Teeth
  Condition or outcome area: Traumatic Pulp Exposure in Children
  2023-01-20 · Subject: Feng Jiao; 蜂胶; Propolis · open the herb record · ClinicalTrials.gov
• Registered trial NCT05627843 Phase 3 Not completed: Recruiting
  Effects of Curcumin on Inflammation and Oxidative Stress in Pediatric Patients on Regular Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Pilot Study
  Condition or outcome area: Pediatric Patients Having Renal Failure and on Regular Hemodialysis
  2022-12-01 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05613361 Phase 3 Not completed: Recruiting
  The Effect of Curcumin Against Colistin-induced Nephrotoxicity
  Condition or outcome area: Acute Kidney Injury|Drug-Induced Nephropathy
  2023-01-01 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05667376 Completed (results not assessed here)
  Efficacy of Curcumin Gel Combined With Non-surgical Periodontal Therapy on Salivary Procalcitonin Level in the Treatment of Periodontitis Patients
  Condition or outcome area: Periodontitis
  2021-01-01 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT05334043 Phase 1 Not completed: Unknown
  Pharmacokinetics and Bioavailability of Curcumin UP 30 Capsules in Healthy Adult Subjects
  Condition or outcome area: Healthy Adult Subjects
  2022-03-23 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04315350 Not completed: Terminated
  The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance
  Condition or outcome area: Insulin Resistance|Non-Alcoholic Fatty Liver Disease
  2019-12-01 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT04028739 Completed (results not assessed here)
  Theracurmin vs Curcumin Bioavailability Study
  Condition or outcome area: Bioavailability
  2019-07-31 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT02369549 Phase 3 Completed (results not assessed here)
  Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
  Condition or outcome area: Chronic Kidney Disease
  2015-09 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT02017353 Phase 2 Completed (results not assessed here)
  Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma
  Condition or outcome area: Endometrial Carcinoma
  2013-10 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01925547 Phase 2 Completed (results not assessed here)
  Micellar Curcumin and Metabolic Syndrome Biomarkers
  Condition or outcome area: Metabolic Syndrome, Protection Against
  2013-07 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01712542 Completed (results not assessed here)
  Curcumin Bioavailability in Glioblastoma Patients
  Condition or outcome area: Patient Harboring Glioblastoma That Will Undergo Surgery
  2012-10 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01490996 Phase 1 / Phase 2 Completed (results not assessed here)
  Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer
  Condition or outcome area: Colonic Cancer|Metastasis
  2012-02 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01179256 Completed (results not assessed here)
  Effect of Supplemental Oral Curcumin in Patients With Atopic Asthma
  Condition or outcome area: Atopic Asthma
  2009-03 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Registered trial NCT01160302 Early_Phase 1 Completed (results not assessed here)
  Curcumin Biomarker Trial in Head and Neck Cancer
  Condition or outcome area: Head and Neck Cancer
  2010-06 · Subject: Curcumin; (1E,4Z,6E)-5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one; C10443; BSPBio_003590; NCGC00095321-01; KBio3_003004; InChI=1/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-13,22,24-25H,1-2H3/b7-3+,8-4+,16-13; curcumin ; diferuloylmethane; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,4,6-trien-3-one · open the ingredient record · ClinicalTrials.gov
• Systematic review registration CRD42023492107 Registered protocol, no results here: Review Ongoing
  Meta-analysis of the antioxidant capacity of Curcumin Bioactive compounds
  Condition or outcome area: The antioxidant capacity expressed by changes in the function and metabolites of all enzymes in charge of the oxidative process in humans
  2023-12-21 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023491610 Registered protocol, no results here: Review Ongoing
  Effectiveness of Herbal Treatments in Cervicovaginal HPV Infection: Meta-Analysis of Randomized Studies
  Condition or outcome area: Servicovaginal HPV
  2023-12-25 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023490581 Registered protocol, no results here: Review Ongoing
  Efficacy of antioxidant-based pharmacological therapies in Autism Spectrum Disorder: A Systematic Review
  Condition or outcome area: Symptom management in patients with ASD
  2023-12-16 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023487941 Registered protocol, no results here: Review Ongoing
  Demethoxycurcumin and bisdemethoxycurcumin are more bioavailable than curcumin in healthy humans: a systematic literature review and meta-analysis
  Condition or outcome area: Turmeric is widely used as a spice but it has also long been used as a traditional medicine and it is used in many dietary supplements. Turmeric usually contains a mixture of three main curcuminoid species: curcumin, demethoxycurcumin and bisdemethoxycurcumin. Curcumin has been the focus of many studies, including randomized controlled trials, investigating numerous potential effects against e.g. inflammation, oxidative stress, cancer, metabolic syndrome, cognitive function decline/Alzheimer’s d
  2023-12-12 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023483768 Registered protocol, no results here: Review Ongoing
  ROLE OF CURCUMIN AND ITS NANOFORMULATIONS IN THE MANAGEMENT OF ORAL SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW
  Condition or outcome area: Oral squamous cell carcinoma (OSCC) is the most common type of oral malignancy, accounting for approximately 80-90% of all malignant neoplasms in the oral cavity. The incidence of oral cancer can vary significantly worldwide, with the oral cavity ranging from the 6th to the 9th most common location for cancer, depending on the country and even specific regions within a country. The incidence of oral cancer is also influenced by factors such as gender and lifestyle choices like tobacco and alcoho
  2023-11-30 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023482358 Registered protocol, no results here: Review Ongoing
  Curcumin, a bioactive supplement for Premenstrual Syndrome and Dysmenorrhea- A Systematic Review of randomized clinical trials
  Condition or outcome area: Premenstrual syndrome (PMS) and dysmenorrhea are prevalent gynecological conditions that affect a significant portion of women worldwide. PMS manifests as a range of physical, emotional, and behavioral symptoms that precede menstruation, while dysmenorrhea is characterized by pain and discomfort during menstruation. Curcumin, a natural compound derived from turmeric, has emerged as a potential therapeutic option due to its diverse pharmacological properties, including anti-inflammatory, antiprol
  2023-11-23 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023479695 Registered protocol, no results here: Review Ongoing
  Anti-tumor effects of curcumin on leukemia: a systematic review
  2023-12-12 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023479195 Registered protocol, no results here: Review Ongoing
  Systematic Review of Curcumin Supplementation on Iron Overload and Antioxidant effect in Beta Thalassemia Patients
  Condition or outcome area: Beta thalassemia major, or cooley's anemia, is the most severe type of the condition. Two beta-globin genes are either absent or broken in this condition. Because individuals with beta thalassemia major require ongoing blood transfusions, the disorder is now referred to as "transfusion-dependent thalassemia
  2023-11-20 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023476932 Registered protocol, no results here: Review Ongoing
  Clinical efficacy and acceptability of natural products in management of radiotherapy-induced oral mucositis: A systematic review
  Condition or outcome area: Radiotherapy-induced oral mucositis
  2023-11-12 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023470083 Registered protocol, no results here: Review Ongoing
  Effectiveness and safety of Curcumin in Autoimmune and Rheumatic Diseases
  Condition or outcome area: Autoimmune and Rheumatic Diseases Curcumin in Autoimmune and Rheumatic Diseases
  2023-10-17 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023469615 Registered protocol, no results here: Review Ongoing
  Premenstrual syndrome attenuation with curcumin: A systematic review and Meta-Analysis
  Condition or outcome area: Premenstrual Syndrome (PMS) is a common condition affecting women, characterized by physical and psychological symptoms tied to hormonal fluctuations in the menstrual cycle. It can range from mild to severe. Medications are often used to alleviate symptoms, but their side effects can be problematic. Curcumin, a compound found in turmeric, has shown promise in reducing PMS symptoms by affecting prostaglandin levels and neurotransmitters, offering a potential natural remedy.
  2023-10-15 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023464474 Registered protocol, no results here: Review Ongoing
  EFFICACY OF CURCUMA LONGA IN RELIEVING PAIN SYMPTOM OF KNEE OSTEOARTHRITIS PATIENTS: A META ANALYSIS OF CLINICAL TRIALS
  Condition or outcome area: Knee osteoarthritis
  2023-10-11 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023463126 Registered protocol, no results here: Review Ongoing
  Nutri-epigenetic effect of curcumin on the treatment of prostate cancer: a systematic review
  2023-11-29 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023462329 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of adjuvant curcumin therapy in colorectal cancer: A systematic review and meta-analysis
  Condition or outcome area: In the most promising therapeutic progress recently, curcumin, a polyphenol from Curcuma, has been suggested to obtain many health-related benefits and pharmacological effects, including its anti-inflammatory and anti-cancer effects. Curcumin is a candidate drug for the prevention and treatment of colorectal cancer.Curcuminoids supplementation for a period of 8 weeks (500 mg/day) can improve ESR and serum levels of CRP in stage-3 CRC subjects and improve the global quality of life and functional
  2023-09-21 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023462093 Registered protocol, no results here: Review Ongoing
  The potential role of turmeric and curcumin as treatment agent for osteoarthritis: A systematic review
  Condition or outcome area: Patients with osteoarthritis condition
  2023-09-29 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023460995 Registered protocol, no results here: Review Ongoing
  Curmin and photoprotection: a systematic review
  Condition or outcome area: The skin is the largest human organ and is the main organ exposed to the harmful effects of exposure to ultraviolet radiation. However, the use of substances with photoprotective properties can prevent the onset of photoaging and skin cancer.
  2023-09-16 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023457942 Registered protocol, no results here: Review Ongoing
  A systematic review and meta-analysis of randomized clinical trials on Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients
  Condition or outcome area: we summarize earlier findings for the effect of curcumin supplementation on glycaemic indices, lipid profile, blood pressure, inflammatory markers, and anthropometric measurements of NAFLD patients.
  2023-09-06 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023454540 Registered protocol, no results here: Review Ongoing
  Pre-clinical Evidence: curcumin as a promising candidate for inhibition of liver cancer growth, a systematic review, and meta-analysis
  2023-09-06 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023448750 Registered protocol, no results here: Review Ongoing
  Effectiveness of Curcumin in Sarcopenia
  Condition or outcome area: Sarcopenia is a progressive and generalized skeletal muscle disorder associated with an increased likelihood of adverse outcomes, including falls, fractures, physical disability, and mortality.
  2023-08-05 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023448363 Registered protocol, no results here: Review Ongoing
  The efficacy and safety of oral curcumin therapy in patients with cancer: a systematic review and meta-analysis.
  Condition or outcome area: Cancer deaths account for 21% of all cases in the U.S. and cancer is the second leading cause of death worldwide.
  2023-08-05 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023448196 Registered protocol, no results here: Review Ongoing
  Antioxidants effects of Curcumin supplementation in among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis
  Condition or outcome area: Metabolic syndrome factors is a broad term referred to several aspects of human health including antioxidants markers
  2023-08-05 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023447628 Registered protocol, no results here: Review Ongoing
  Targeting cognitive function with curcumin in humans: A systematic review and meta-analysis
  Condition or outcome area: The association of curcumin with cognitive function in humans.
  2023-08-02 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023447460 Registered protocol, no results here: Review Ongoing
  Anti-inflammatory effects of Curcumin supplementation in among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis
  Condition or outcome area: Metabolic syndrome factors is a broad term referred to several aspects of human health including inflammatory markers.
  2023-08-01 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023446682 Registered protocol, no results here: Review Ongoing
  Chemopreventive efficacy of Curcumin in the management of Oral submucous fibrosis- A systematic review
  Condition or outcome area: Oral submucous fibrosis (OSMF) is a potentially malignant disorder of oral cavity primarily caused by areca nut chewing. Prevalence of OSMF is reported between .03% and 30% irrespective of areca nut habit. OSMF is a major global health issue because of its high malignant transformation rate, upto 15-30% according to different studies.OSMF is characterized by burning sensation on having hot and spicy food and stiffness and blanching of the oral mucosa leading to restricted mouth opening.
  2023-07-31 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023441075 Registered protocol, no results here: Review Ongoing
  Curcumin and cognitive impairment: A systematic review and meta-analysis
  Condition or outcome area: cognitive impairment
  2023-07-10 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023440612 Registered protocol, no results here: Review Ongoing
  Effects of turmeric/curcumin supplementation on anthropometric indices in subjects with prediabetes and type 2 diabetes mellitus: A systematic review and dose-response meta-analysis of randomized controlled Trials
  Condition or outcome area: In this review, the effect of turmeric/curcumin on body composition in patients with prediabetes and type 2 diabetes mellitus will be studied.
  2023-07-10 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023439718 Registered protocol, no results here: Review Ongoing
  Curcumin as a potential agent for inhibition of glioma growth: a systematic review and meta-analysis
  2023-07-05 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023439564 Registered protocol, no results here: Review Ongoing
  Effects of curcumin nanoparticles on cognitive impairment in Alzheimer's disease: a systematic review and meta-analysis of preclinical studies
  2023-07-05 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023432665 Registered protocol, no results here: Review Ongoing
  Mapping and exploring the therapeutic potential of natural bioactive compound Curcumin in NAFLD: A Systematic Review & Meta-Analysis
  Condition or outcome area: NonAlcoholic Fatty Liver Disease Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat builds up in the liver.
  2023-06-16 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Systematic review registration CRD42023426108 Registered protocol, no results here: Review Ongoing
  Efficacy and safety of curcumin therapy in the treatment of knee osteoarthritis: A Bayesian network meta-analysis
  Condition or outcome area: Knee osteoarthritis (KOA) is a degenerative osteoarthritis characterized by joint inflammation and progressive articular cartilage degeneration. The main clinical manifestations of KOA are joint swelling, pain, stiffness, and limited mobility, which seriously affect patients' self-care ability and reduce their quality of life.
  2023-05-23 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record
• Publication PMID 32721999 Research model: Cell Experiment
  Resveratrol, Curcumin and Piperine Alter Human Glyoxalase 1 in MCF-7 Breast Cancer Cells
  Condition or outcome area: mitochondrial dysfunction; breast cancer; cancer; Breast cancer
  Int J Mol Sci · 2020 · Subject: Piperine; 94-62-2; 1-Piperoylpiperidine; Piperin; Bioperine; 7780-20-3; Piperoylpiperidine; FEMA No. 2909; (E,E)-1-piperoylpiperidine; Piperidine, 1-piperoyl-, (E,E)- · open the ingredient record · DOI 10.3390/ijms21155244
• Publication PMID 36070663 Research model: Animal Experiment
  Perillyl alcohol attenuates chronic restraint stress aggravated dextran sulfate sodium-induced ulcerative colitis by modulating TLR4/NF-κB and JAK2/STAT3 signaling pathways
  Condition or outcome area: chronic inflammatory immune bowel disease; ulcerative colitis; Ulcerative colitis; chronic inflammation; decreased ulcerations
  Phytomedicine · 2022 · Subject: Perillyl alcohol; 536-59-4; Perilla alcohol; Perillol; Isocarveol; p-Mentha-1,8-dien-7-ol; Hydrocumin alcohol; 1-Cyclohexene-1-methanol, 4-(1-methylethenyl)-; Dihydrocuminyl alcohol; Iso-carveol · open the ingredient record · DOI 10.1016/j.phymed.2022.154415
• Publication PMID 35030388 Research model: Animal & Cell Experiment
  Perillyl alcohol attenuates rheumatoid arthritis via regulating TLR4/NF-κB and Keap1/Nrf2 signaling pathways: A comprehensive study onin-vitro and in-vivo experimental models
  Condition or outcome area: joint inflammation; arthritis; Rheumatoid arthritis; bone erosion; rheumatoid arthritis; chronic and idiopathic autoimmune disorder; pannus
  Phytomedicine · 2022 · Subject: Perillyl alcohol; 536-59-4; Perilla alcohol; Perillol; Isocarveol; p-Mentha-1,8-dien-7-ol; Hydrocumin alcohol; 1-Cyclohexene-1-methanol, 4-(1-methylethenyl)-; Dihydrocuminyl alcohol; Iso-carveol · open the ingredient record · DOI 10.1016/j.phymed.2022.153926
• Publication PMID 34929480 Research model: Animal & Cell Experiment
  Perillyl alcohol inhibits keratinocyte proliferation and attenuates imiquimod-induced psoriasis like skin-inflammation by modulating NF-κB and STAT3 signaling pathways
  Condition or outcome area: psoriatic like skin inflammation; chronic inflammatory and proliferative skin disease; epidermal hyperplasia; splenomegaly; imiquimod; skin lesions; psoriasis; acanthosis; psoriasis-like skin inflammation; Psoriasis; hyper-keratosis
  Int Immunopharmacol · 2021 · Subject: Perillyl alcohol; 536-59-4; Perilla alcohol; Perillol; Isocarveol; p-Mentha-1,8-dien-7-ol; Hydrocumin alcohol; 1-Cyclohexene-1-methanol, 4-(1-methylethenyl)-; Dihydrocuminyl alcohol; Iso-carveol · open the ingredient record · DOI 10.1016/j.intimp.2021.108436
• Publication PMID 33649109 Research model: Animal Experiment
  Perillyl alcohol reduces parasite sequestration and cerebrovascular dysfunction during experimental cerebral malaria
  Condition or outcome area: vascular dysfunction; Cerebral malaria; cerebrovascular dysfunction; inflammatory infiltrates; immunovasculopathy; cerebral oedema; Cerebral Malaria
  Antimicrob Agents Chemother · 2021 · Subject: Perillyl alcohol; 536-59-4; Perilla alcohol; Perillol; Isocarveol; p-Mentha-1,8-dien-7-ol; Hydrocumin alcohol; 1-Cyclohexene-1-methanol, 4-(1-methylethenyl)-; Dihydrocuminyl alcohol; Iso-carveol · open the ingredient record · DOI 10.1128/AAC.00004-21
• Publication PMID 35204061 Research model: Animal & Cell Experiment
  Therapeutic Potential of Perillaldehyde in Ameliorating Vulvovaginal Candidiasis by Reducing Vaginal Oxidative Stress and Apoptosis
  Condition or outcome area: Vulvovaginal candidiasis; Candida albicans
  Antioxidants (Basel) · 2022 · Subject: Perillaldehyde; Perillyl aldehyde; 2111-75-3; Perilla aldehyde; Perillal; Perillic aldehyde; P-Mentha-1,8-dien-7-al; Dihydrocuminyl aldehyde; 1-Cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-; 4-prop-1-en-2-ylcyclohexene-1-carbaldehyde · open the ingredient record · DOI 10.3390/antiox11020178
• Publication PMID 34903262 Research model: Animal & Cell Experiment
  Perillaldehyde improves cognitive function in vivo and in vitro by inhibiting neuronal damage via blocking TRPM2/NMDAR pathway
  Condition or outcome area: vascular dementia; cognitive dysfunction syndrome; cerebrovascular diseases; epilepsy; insomnia; Vascular cognitive dysfunction; central nervous system diseases
  Chin Med · 2021 · Subject: Perillaldehyde; Perillyl aldehyde; 2111-75-3; Perilla aldehyde; Perillal; Perillic aldehyde; P-Mentha-1,8-dien-7-al; Dihydrocuminyl aldehyde; 1-Cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-; 4-prop-1-en-2-ylcyclohexene-1-carbaldehyde · open the ingredient record · DOI 10.1186/s13020-021-00545-9
• Publication PMID 34738877 Research model: Cell Experiment
  Perillaldehyde inhibits bone metastasis and receptor activator of nuclear factor-κB ligand (RANKL) signaling-induced osteoclastogenesis in prostate cancer cell lines
  Condition or outcome area: prostate cancer; PCa; cancer
  Bioengineered · 2021 · Subject: Perillaldehyde; Perillyl aldehyde; 2111-75-3; Perilla aldehyde; Perillal; Perillic aldehyde; P-Mentha-1,8-dien-7-al; Dihydrocuminyl aldehyde; 1-Cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-; 4-prop-1-en-2-ylcyclohexene-1-carbaldehyde · open the ingredient record · DOI 10.1080/21655979.2021.2001237
• Publication PMID 32822688 Research model: Animal & Cell Experiment
  Perillaldehyde: A promising antifungal agent to treat oropharyngeal candidiasis
  Condition or outcome area: oropharyngeal candidiasis
  Biochem Pharmacol · 2020 · Subject: Perillaldehyde; Perillyl aldehyde; 2111-75-3; Perilla aldehyde; Perillal; Perillic aldehyde; P-Mentha-1,8-dien-7-al; Dihydrocuminyl aldehyde; 1-Cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-; 4-prop-1-en-2-ylcyclohexene-1-carbaldehyde · open the ingredient record · DOI 10.1016/j.bcp.2020.114201
• Publication PMID 34883248 Research model: Animal Experiment
  Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats
  Condition or outcome area: vascular dysfunction; tumor; hypertension
  Biochim Biophys Acta Mol Basis Dis · 2022 · Subject: Hexahydrocurcumin; 36062-05-2; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)heptan-3-one; Curcumin, hexahydro-; 3-Heptanone, 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-; RNL5XJ2BA7; C17826; (RS)-5-Hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-3-heptanone; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-3-heptanone; UNII-RNL5XJ2BA7 · open the ingredient record · DOI 10.1016/j.bbadis.2021.166317
• Publication PMID 35729841 Research model: Animal Experiment
  Demethoxycurcumin mitigates inflammatory responses in lumbar disc herniation via MAPK and NF-κB pathways in vivo and in vitro
  Condition or outcome area: lumbar disc herniation; inflammation-associated diseases; inflammatory radicular pain
  Int Immunopharmacol · 2022 · Subject: Demethoxycurcumin; 22608-11-3; 24939-17-1; curcumin II; monodemethoxycurcumin; desmethoxycurcumin; BHCFM; Demethoxy Curcumin; 4-Hydroxycinnamoyl(feroyl)methane; 33171-16-3 · open the ingredient record · DOI 10.1016/j.intimp.2022.108914
• Publication PMID 33582110 Research model: Cell Experiment
  Dimethoxycurcumin reduces proliferation and induces apoptosis in renal tumor cells more efficiently than demethoxycurcumin and curcumin
  Condition or outcome area: renal adenocarcinoma
  Chem Biol Interact · 2021 · Subject: Demethoxycurcumin; 22608-11-3; 24939-17-1; curcumin II; monodemethoxycurcumin; desmethoxycurcumin; BHCFM; Demethoxy Curcumin; 4-Hydroxycinnamoyl(feroyl)methane; 33171-16-3 · open the ingredient record · DOI 10.1016/j.cbi.2021.109410
• Publication PMID 32188144 Research model: Cell Experiment
  Dual Targeting of the p38 MAPK-HO-1 Axis and cIAP1/XIAP by Demethoxycurcumin Triggers Caspase-Mediated Apoptotic Cell Death in Oral Squamous Cell Carcinoma Cells
  Condition or outcome area: cancers; oral squamous cell carcinoma; head and neck cancers
  Cancers (Basel) · 2020 · Subject: Demethoxycurcumin; 22608-11-3; 24939-17-1; curcumin II; monodemethoxycurcumin; desmethoxycurcumin; BHCFM; Demethoxy Curcumin; 4-Hydroxycinnamoyl(feroyl)methane; 33171-16-3 · open the ingredient record · DOI 10.3390/cancers12030703
• Publication PMID 36676983 Research model: Cell Experiment
  Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
  Condition or outcome area: Chronic myeloid leukemia; myeloproliferative haematological malignancy
  Metabolites · 2023 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3390/metabo13010058
• Publication PMID 36610148 Research model: Animal & Cell Experiment
  Curcumin treatment suppresses cachexia-associated adipose wasting in mice by blocking the cAMP/PKA/CREB signaling pathway
  Condition or outcome area: cancer cachexia; Cachexia; adipose atrophy; tumor; C26 tumors; cachexia; cancer
  Phytomedicine · 2023 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.1016/j.phymed.2022.154563
• Publication PMID 36552609 Research model: Animal Experiment
  β-Cell Autophagy Pathway and Endoplasmic Reticulum Stress Regulating-Role of Liposomal Curcumin in Experimental Diabetes Mellitus: A Molecular and Morphometric Study
  Condition or outcome area: type I diabetes
  Antioxidants (Basel) · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3390/antiox11122400
• Publication PMID 36538966 Research model: Cell Experiment
  Effective role of Curcumin on expression regulation of EZH2 histone methyltransferase as a dynamic epigenetic factor in osteogenic differentiation of human mesenchymal stem cells
  Condition or outcome area: osteogenesis
  Biochim Biophys Acta Gene Regul Mech · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.1016/j.bbagrm.2022.194903
• Publication PMID 36499098 Research model: Cell Experiment
  New Insights into Dose-Dependent Effects of Curcumin on ARPE-19 Cells
  Condition or outcome area: Age-Related Macular Degeneration; proliferative vitreoretinopathy; ocular diseases
  Int J Mol Sci · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3390/ijms232314771
• Publication PMID 36432477 Research model: Clinical Experiment
  MACC1-Dependent Antitumor Effect of Curcumin in Colorectal Cancer
  Condition or outcome area: tumor; colon cancer; cancer; colorectal cancer
  Nutrients · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3390/nu14224792
• Publication PMID 36359867 Research model: Cell Experiment
  Curcumin Reprograms TAMs from a Protumor Phenotype towards an Antitumor Phenotype via Inhibiting MAO-A/STAT6 Pathway
  Condition or outcome area: tumor
  Cells · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3390/cells11213473
• Publication PMID 36353208 Research model: Animal & Cell Experiment
  Curcumin alleviates experimental colitis via a potential mechanism involving memory B cells and Bcl-6-Syk-BLNK signaling
  Condition or outcome area: Immune dysfunction; Colitis; autoimmune diseases; colitis; inflammatory bowel disease
  World J Gastroenterol · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3748/wjg.v28.i40.5865
• Publication PMID 36300880 Research model: Cell Experiment
  Modulation of the activity of histone lysine methyltransferases and demethylases by curcumin analog in leukaemia cells
  Condition or outcome area: HKDMs; cancer
  J Cell Mol Med · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.1111/jcmm.17589
• Publication PMID 36243116 Research model: Cell Experiment
  The effect of curcumin on the cadmium-induced mitochondrial apoptosis pathway by metallothionein 2A regulation
  Life Sci · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.1016/j.lfs.2022.121076
• Publication PMID 36238646 Research model: Animal & Cell Experiment
  Curcumin Enhanced Ionizing Radiation-Induced Immunogenic Cell Death in Glioma Cells through Endoplasmic Reticulum Stress Signaling Pathways
  Condition or outcome area: glioma; immunogenic cell death; tumor
  Oxid Med Cell Longev · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.1155/2022/5424411
• Publication PMID 36237434 Research model: Cell Experiment
  Curcumin affects function of Hsp90 and drug efflux pump of Candida albicans
  Condition or outcome area: cancer; candidiasis
  Front Cell Infect Microbiol · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3389/fcimb.2022.944611
• Publication PMID 36196887 Research model: Animal & Cell Experiment
  Effect of curcumin on regulatory B cells in chronic colitis mice involving TLR/MyD88 signaling pathway
  Condition or outcome area: colitis; ulcerative colitis; chronic colitis
  Phytother Res · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.1002/ptr.7656
• Publication PMID 36155114 Research model: Cell Experiment
  Curcumin and capsaicin regulate apoptosis and alleviate intestinal inflammation induced by Clostridioides difficile in vitro
  Condition or outcome area: Clostridioides difficile infection
  Ann Clin Microbiol Antimicrob · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.1186/s12941-022-00533-3
• Publication PMID 36120325 Research model: Clinical & Animal Experiment
  Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms
  Condition or outcome area: psoriatic dermatitis; tumor; chronic and immune-mediated inflammatory skin disease; psoriasis; Psoriasis
  Front Pharmacol · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3389/fphar.2022.903160
• Publication PMID 36014807 Research model: Cell Experiment
  Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation
  Condition or outcome area: insulin resistance syndrome
  Nutrients · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.3390/nu14163301
• Publication PMID 36007676 Research model: Cell Experiment
  Mechanism of apoptosis activation by Curcumin rescued mutant p53Y220C in human pancreatic cancer
  Condition or outcome area: tumor; pancreatic cancer; tumors
  Biochim Biophys Acta Mol Cell Res · 2022 · Subject: Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Curcuma; Gelbwurz; Haldar; Curcumin I · open the ingredient record · DOI 10.1016/j.bbamcr.2022.119343